Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Impact · against what's priced in

The positive Phase 1 data for Sofe-M provides a concrete catalyst for Lilly's oncology pipeline, which the market has largely ignored in favor of GLP-1 metrics. While not moving the needle on 2026 revenue, it validates an unpriced growth lever that could help the company exceed the 30.2% long-term CAGR the current price requires.

LLY+0.40

Challenges what's priced in

The price assumes